IFP Advisors Inc Purchases 5,313 Shares of Boston Scientific Corporation $BSX

IFP Advisors Inc lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 31.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,988 shares of the medical equipment provider's stock after acquiring an additional 5,313 shares during the quarter. IFP Advisors Inc's holdings in Boston Scientific were worth $2,372,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in BSX. Callan Family Office LLC raised its holdings in Boston Scientific by 294.7% in the second quarter. Callan Family Office LLC now owns 28,397 shares of the medical equipment provider's stock worth $3,050,000 after purchasing an additional 21,203 shares in the last quarter. Blair William & Co. IL raised its holdings in Boston Scientific by 0.7% in the second quarter. Blair William & Co. IL now owns 118,768 shares of the medical equipment provider's stock worth $12,757,000 after purchasing an additional 826 shares in the last quarter. US Bancorp DE raised its holdings in Boston Scientific by 0.7% in the second quarter. US Bancorp DE now owns 353,845 shares of the medical equipment provider's stock worth $38,006,000 after purchasing an additional 2,327 shares in the last quarter. Trifecta Capital Advisors LLC raised its holdings in Boston Scientific by 6.9% in the second quarter. Trifecta Capital Advisors LLC now owns 46,411 shares of the medical equipment provider's stock worth $4,985,000 after purchasing an additional 3,010 shares in the last quarter. Finally, Maryland State Retirement & Pension System raised its holdings in Boston Scientific by 4.5% in the second quarter. Maryland State Retirement & Pension System now owns 71,745 shares of the medical equipment provider's stock worth $7,706,000 after purchasing an additional 3,059 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $95.41 on Friday. The business's 50 day moving average price is $101.98 and its 200 day moving average price is $101.86. The firm has a market cap of $141.38 billion, a P/E ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 in the last ninety days. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Robert W. Baird boosted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, October 1st. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. UBS Group boosted their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Truist Financial boosted their price target on Boston Scientific from $125.00 to $129.00 and gave the stock a "buy" rating in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.